Evidence map›Paper›PMID 41160784›Full record

ArticleJCO global oncology2025

Cervical and Tumor-Associated Microbiomes in Botswana Women With and Without HIV With Carcinoma of the Cervix Before and After Definitive Chemoradiation.

Travis T Sims, Kyoko Yoshida-Court, Molly B El Alam, Pleasure Ramatlho, Rebecca Ketlametswe, Matthew S Ning, Erle S Robertson, Kathleen M Schmeler, Lauren E Colbert, Ann H Klopp and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO global oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Travis T SimsDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-1975-0795
Kyoko Yoshida-CourtDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-7558-9943
Molly B El AlamDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Pleasure RamatlhoBotswana-University of Pennsylvania Partnership, Gaborone, Botswana.ORCID 0000-0002-4314-8377
Rebecca KetlametsweBotswana-University of Pennsylvania Partnership, Gaborone, Botswana.
Matthew S NingDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-2932-5584
Erle S RobertsonDepartment of Otorhinolaryngology-Head and Neck Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-6088-2979
Kathleen M SchmelerDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-9670-4189
Lauren E ColbertDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-5806-4339
Ann H KloppDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-2081-0735
Surbhi GroverBotswana-University of Pennsylvania Partnership, Gaborone, Botswana.ORCID 0000-0001-7443-5937

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam · 2014 to 2026
$146.4M
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Eric Andrew Ross · 1985 to 2026
$138.8M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Suzanne AW Fuqua · 2007 to 2026
$73.9M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI David B. Solit · 2001 to 2026
$63.0M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V. · 1996 to 2024
$57.4M
ZACOPRIDE VS METOCLOPRAMIDE--EFFECT ON LOWER ESOPHAGEAL SPHINCTERM01RR000847 · NCRR · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI KRAMER, CHRISTOPHER M. · 1985 to 2010
$48.1M
Convalescent Plasma to Limit Coronavirus Associated ComplicationsUL1TR003167 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KARP, DANIEL D, MCPHERSON, DAVID D · 2019 to 2023
$45.3M
BLRD VA IK2 BX004360NCATS NIH HHS KL2 TR000370NCATS NIH HHS UH3 TR000943NCATS NIH HHS UL1 TR000371NCATS NIH HHS UL1 TR001863NCATS NIH HHS UL1 TR003167NCI NIH HHS K01 CA181292NCI NIH HHS K07 CA113641NCI NIH HHS K08 CA160692NCI NIH HHS K08 CA234333NCI NIH HHS K12 CA088084NCI NIH HHS L30 CA123720NCI NIH HHS P01 CA114046NCI NIH HHS P01 CA117969NCI NIH HHS P30 CA006927NCI NIH HHS P30 CA014520NCI NIH HHS P30 CA015704NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA125123NCI NIH HHS P30 CA177558NCI NIH HHS P50 CA070907NCI NIH HHS P50 CA083639NCI NIH HHS P50 CA092629NCI NIH HHS P50 CA097007NCI NIH HHS P50 CA098258NCI NIH HHS P50 CA136393NCI NIH HHS P50 CA140388NCI NIH HHS P50 CA217685NCI NIH HHS P50 CA221703NCI NIH HHS P50 CA221707NCI NIH HHS P50 CA281701NCI NIH HHS R01 CA026582NCI NIH HHS R01 CA109298NCI NIH HHS R01 CA127328NCI NIH HHS R01 CA131274NCI NIH HHS R01 CA154710NCI NIH HHS R01 CA171338NCI NIH HHS R01 CA172741NCI NIH HHS R01 CA173877NCI NIH HHS R01 CA178744NCI NIH HHS R01 CA197916NCI NIH HHS R01 CA207244NCI NIH HHS R01 CA219896NCI NIH HHS R01 CA223772NCI NIH HHS R01 CA227622NCI NIH HHS R01 CA247220NCI NIH HHS R01 CA255074NCI NIH HHS R01 CA255960NCI NIH HHS R01 CA284684NCI NIH HHS R01 CA306089NCI NIH HHS R03 CA128110NCI NIH HHS R03 CA135679NCI NIH HHS R03 CA142072NCI NIH HHS R03 CA178495NCI NIH HHS R03 CA188162NCI NIH HHS R21 CA129906NCI NIH HHS R21 CA178450NCI NIH HHS R21 CA208461NCI NIH HHS R21 CA226200NCI NIH HHS R25 CA056452NCI NIH HHS R25 CA057730NCI NIH HHS R37 CA242006NCI NIH HHS R50 CA243707NCI NIH HHS T32 CA009666NCI NIH HHS T32 CA101642NCI NIH HHS U01 CA152756NCI NIH HHS U01 CA154601NCI NIH HHS U01 CA168394NCI NIH HHS U01 CA213759NCI NIH HHS U01 CA217842NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS U54 CA210181NCI NIH HHS U54 CA224065NCI NIH HHS U54 CA224083NCI NIH HHS UG1 CA233191NCI NIH HHS UM1 CA186644NCI NIH HHS UM1 CA186686NCI NIH HHS UM1 CA186691NCRR NIH HHS M01 RR000847NHLBI NIH HHS R01 HL157273NIAID NIH HHS R01 AI083761NIAMS NIH HHS K08 AR079587NIBIB NIH HHS P41 EB015902NIDCR NIH HHS F31 DE031502NIDCR NIH HHS R56 DE025248NIGMS NIH HHS F32 GM016926NIH HHS DP2 OD007044NINDS NIH HHS R03 NS050840NLM NIH HHS T15 LM007093
6 · The paper itself

Abstract

purposeCervical cancer remains a significant public health concern globally and particularly in sub-Saharan Africa, where high rates of HIV infection exacerbate cervical cancer incidence. Understanding the cervical microbiome and its role in cancer progression is essential, especially in regions where both cervical cancer incidence and HIV prevalence are high. This study aimed to characterize the cervical microbiome in women living with HIV (WLWH) and HIV-negative women with squamous cell carcinoma of the cervix in Botswana, compare the microbiome between before and after chemoradiation therapy (CRT) in WLWH, and assess the prognostic value of specific microbial taxa for overall survival (OS) in WLWH. PATIENTS AND

methodsCervical samples were collected from women with cervical cancer presenting to one hospital in 2018-2019. Patients' clinical data, including HIV status, were recorded. Microbial composition was analyzed using 16S rRNA gene sequencing. Microbiome diversity and composition were evaluated using alpha and beta diversity metrics. Differential microbial abundance was analyzed using linear discriminant analysis effect size. The association between microbial taxa and OS was explored using Cox proportional hazards regression.

resultsWLWH (n = 42) had a significantly lower Pielou evenness index than HIV-negative women (n = 11; 0.6

conclusionMicrobiome profiles differ between WLWH and HIV-negative women with cervical cancer in Botswana. The microbiome might have prognostic significance. Future research is needed to better understand the significance of the microbiota in cervical cancer progression and treatment outcomes and the potential role of microbiome-targeted interventions.

Indexed as

Cervix UteriChemoradiotherapyHIV InfectionsMicrobiotaUterine Cervical NeoplasmsAdultBotswanaFemaleHumansMiddle Aged

Identifiers

PMID41160784
PMCPMC12688299

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.